Published • loading... • Updated
Moderna stock soars 177%, Merck jumps 12% after cancer vaccine shows promise in late-stage trial
Summary by Ground News
4 Articles
4 Articles
Moderna, in collaboration with Merck, achieved success in Phase 3 clinical trials for a personalized mRNA cancer vaccine. Significant results were obtained in high-risk melanoma patients, demonstrating a reduction in the risk of recurrence and metastasis, leading to a surge in the stock price amidst high market valuations. While the challenge of optimizing the production process remains, the initiative has demonstrated the potential for a succes…
Moderna shares double as cancer vaccine data rekindles investor hopes
Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer therapy developed with Merck sent investors piling into the stock.
·London, United Kingdom
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left1Leaning Right1Center2Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 25%
C 50%
R 25%
Factuality
To view factuality data please Upgrade to Premium
